Exhibit 99 Financial Results for the Three Months Ended September 30: 2025 Compared to 2024 Financial Results for the Nine Months Ended September 30: 2025 Compared to 2024 Financial Outlook "Our top priority remains building sustainable profitability through disciplined cost management and targeted investments in high- return initiatives. As a result, we delivered solid margins and strong cash flow in the third quarter of 2025, further strengthening our balance sheet. While we expect revenue headwinds to co ...

Exhibit 99.1 Texas Roadhouse, Inc. Announces Third Quarter 2025 Results Declares Quarterly Dividend of $0.68 per Share LOUISVILLE, KY. (November 6, 2025) – Texas Roadhouse, Inc. (NasdaqGS: TXRH), today announced financial results for the 13 and 39 weeks ended September 30, 2025. Financial Results Financial results for the 13 and 39 weeks ended September 30, 2025 and September 24, 2024 were as follows: | | 13 Weeks Ended | | | 39 Weeks Ended | | | | --- | --- | --- | --- | --- | --- | --- | | ($000's, except ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the transition period from ____________ to____________ Commission file number: 001-11015 Pursuit Attractions and Hospitality, Inc. (Exact name of registrant as specified in its charter) Delaware 36-1169950 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANG ...

Exhibit 99.1 Carlsmed®Reports Third Quarter 2025 Financial Results and Raises Full-Year Guidance Third quarter revenue of $13.1 million, representing 98% growth YoY Raising full year 2025 revenue guidance to $49 million - $50 million CARLSBAD, Calif., November 6, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the third quarter ended September 30 ...

Exhibit 99.1 Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update 89% of evaluable mipletamig patients achieve remission in combination therapy for frontline AML across two trials Introduces first trispecific molecules, APVO451 and APVO452, advancing therapies designed to overcome immune suppression in certain solid tumors Both molecules leverage Aptevo's unique use of the CRIS-7-derived CD3 binding domain, associated with favorable safety outcomes in the clinic; CD3 T-cell enga ...

Dropbox Announces Fiscal 2025 Third Quarter Results Third Quarter GAAP Operating Margin of 27.5% and Non-GAAP Operating Margin of 41.1% Net Cash Provided by Operating Activities of $302.1 Million and Free Cash Flow of $293.7 Million Revenue of $634.4 Million, down 0.7% year-over-year; on a constant currency basis, down 1.2% year-over-year SAN FRANCISCO, Calif. - November 6, 2025 - Dropbox, Inc. (NASDAQ: DBX), today announced financial results for its third quarter ended September 30, 2025. Dropbox plans to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39184 SWK Holdings Corporation (Exact Name of Registrant as Specified in its Charter) 5956 Sherry Lane, Suite 650 Dallas, TX 75225 (Address of Principal Executive Offic ...

OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One): ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from __________ to __________ Commission File Number: 001-35975 Gogo Inc. (Exact name of registrant as specified in its charter) (State or other jurisdictio ...

Exhibit 99.1 Inseego Reports Third Quarter 2025 Financial Results Q3 2025 revenue of $45.9 million, second consecutive quarter of sequential growth Q3 2025 Adjusted EBITDA of $5.8 million and GAAP Net Income of $1.4 million Nabil Bukhari and Stephen Bye join Inseego Board of Directors SAN DIEGO—November 6, 2025—Inseego Corp. (Nasdaq: INSG) (the "Company"), a global leader in 5G mobile broadband and 5G fixed wireless access (FWA) solutions, today reported its results for the third quarter of 2025 ended Septe ...

Exhibit 99.1 OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update -- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patients with metastatic breast cancer -- Clinical data from OKI-219 PIKture-01 single agent and fulvestrant combination arms are maturing and is now expected to be reported together with initial data from the ...